Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued …,

Clinical studies ongoing to establish optimal dose regimen and activity with weekly dosing. MP0317 (FAP X CD40):. Investigational New Drug …, Clinical studies ongoing to establish optimal dose regimen and activity with weekly dosing. MP0317 (FAP X CD40):. Investigational New Drug …, Read More

Scroll to Top